This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
In this brief commentary, the renowned cardiologist Dr Mark Petrie from Glasgow, UK, provides an overview of the close association of type 2 diabetes and CV disease and summaries latest clinical data on CV risk reduction with GLP-1 RAs abd SGLT2 inhibators as presented at ESC 2020. He puts these findings into context with the most recent ESC/EASD guidelines on the recommend use of these newer glucose-lowering drugs in patients with T2D and established or high risk for CV disease.
He then explores the current under-utilization of GLP-1 RAs and suggests solutions how to overcome some of these obstacles in clinical practice.
Made for: Diabetologists, Endocrinologists, Cardiologists, Primary Care Physicians
Disease areas: Diabetes, Cardiovascular Disease
Developed by: Medscape